Metabolic Dysfunction-Associated Steatohepatitis

The investigational drug for late-stage MASH will now get more robust, proactive guidance from U.S. and European regulators.

In mouse models, semaglutide benefited the liver even in the absence of weight loss. The benefit appears to come via a particular type of liver cell.

The company says it made an upfront payment of $25 million for a global license to develop and commercialize the ARO-PHPLA3.

The FDA has approved two drugs for treatment of the condition, Rezdiffra (resmetirom) and Wegovy (semaglutide), the weight loss drug.